D. Antonio, M. Dogan, C. Hamroun, D. Mati, M. Zerrouki et al., Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification, Rev Neurol, vol.172, issue.10, pp.572-80, 2016.

G. Gourdon and G. Meola, Myotonic dystrophies: state of the art of new therapeutic developments for the CNS, Front Cell Neurosci, vol.11, p.101, 2017.

C. Dogan, D. Antonio, M. Hamroun, D. Varet, H. Fabbro et al., Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a Nationwide multiple databases crosssectional observational study, PLoS One, vol.11, issue.2, p.148264, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01274908

E. Passeri, E. Bugiardini, V. A. Sansone, R. Valaperta, C. E. Ambrosi et al., Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies, J Neurol Sci, vol.331, issue.1-2, pp.132-137, 2013.

M. C. Ørngreen, P. Arlien-søborg, M. Duno, J. M. Hertz, and J. Vissing, Endocrine function in 97 patients with myotonic dystrophy type 1, J Neurol, vol.259, issue.5, pp.912-932, 2012.

D. Abbott, N. E. Johnson, and L. A. Cannon-albright, A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy, Muscle Nerve, vol.54, issue.4, pp.783-788, 2016.

M. Bianchi, E. Leoncini, M. Masciullo, A. Modoni, S. M. Gadalla et al., Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors, J Neurol, vol.263, issue.3, pp.492-500, 2016.

R. Fernández-torrón, M. García-puga, J. Emparanza, M. Maneiro, A. Cobo et al., Cancer risk in DM1 is sex-related and linked to miRNA-200/ 141 downregulation, Neurology, vol.20, issue.12, pp.1250-1257, 2016.

S. M. Gadalla, R. M. Pfeiffer, S. Y. Kristinsson, M. Björkholm, O. Landgren et al., Brain tumors in patients with myotonic dystrophy: a population-based study, Eur J Neurol, vol.23, issue.3, pp.542-549, 2016.

M. Das, R. T. Moxley, J. E. Hilbert, W. B. Martens, L. Letren et al., Correlates of tumor development in patients with myotonic dystrophy, J Neurol, vol.259, issue.10, pp.2161-2167, 2012.

Y. Wang, R. M. Pfeiffer, R. Alsaggaf, W. Meeraus, J. C. Gage et al., Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. clinical practice research datalink, Int J Cancer, vol.142, issue.6, pp.1174-81, 2017.

J. I. Emparanza, L. De-munain, A. Greene, M. H. Matheu, A. Fernández-torrón et al., Cancer phenotype in myotonic dystrophy patients: results from a meta-analysis, Muscle Nerve, vol.58, issue.4, pp.517-539, 2018.

A. K. Win, P. G. Perattur, J. S. Pulido, C. M. Pulido, and N. M. Lindor, Increased cancer risks in myotonic dystrophy, Mayo Clin Proc, vol.87, issue.2, pp.130-135, 2012.

S. M. Gadalla, M. Lund, R. M. Pfeiffer, S. Gørtz, C. M. Mueller et al., Cancer risk among patients with myotonic muscular dystrophy, JAMA, vol.306, issue.22, pp.2480-2486, 2011.

R. Alsaggaf, Y. Wang, C. Marini-bettolo, L. Wood, N. Nikolenko et al., Benign and malignant tumors in the UK myotonic dystrophy patient registry, Muscle Nerve, vol.57, issue.2, pp.316-336, 2018.

G. Russ, C. Bigorgne, B. Royer, A. Rouxel, and M. Bienvenu-perrard, The thyroid imaging reporting and data system (TIRADS) for ultrasound of the thyroid, J Radiol, vol.92, issue.7-8, pp.701-714, 2011.

D. Dauksiene, J. Petkeviciene, J. Klumbiene, R. Verkauskiene, J. Vainikonyte-kristapone et al., Factors associated with the prevalence of thyroid nodules and goiter in middle-aged Euthyroid subjects, Int J Endocrinol, p.8401518, 2017.

L. Furuya-kanamori, K. Bell, J. Clark, P. Glasziou, and S. Doi, Prevalence of differentiated thyroid Cancer in autopsy studies over six decades: a metaanalysis, J Clin Oncol, vol.34, issue.30, pp.3672-3681, 2016.

Y. S. Lee, H. Lim, H. Chang, and C. S. Park, Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy, J Korean Med Sci, vol.29, issue.5, pp.676-685, 2014.

Y. J. Cha, J. Y. Pyo, S. Hong, J. Y. Seok, K. Kim et al., Thyroid fine-needle aspiration cytology practice in Korea, J Pathol Transl Med, vol.51, issue.6, pp.521-528, 2017.

B. R. Haugen, A. M. Sawka, E. K. Alexander, K. C. Bible, P. Caturegli et al., American Thyroid Association guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features, Thyroid, vol.27, issue.4, pp.481-484, 2017.

H. Lim, S. S. Devesa, J. A. Sosa, D. Check, and C. M. Kitahara, Trends in thyroid Cancer incidence and mortality in the United States, JAMA, vol.317, issue.13, pp.1338-1386, 1974.

A. Miyauchi, Clinical trials of active surveillance of papillary microcarcinoma of the thyroid, World J Surg, vol.40, issue.3, pp.516-538, 2016.

T. H. Brix, P. S. Hansen, K. O. Kyvik, and L. Hegedüs, Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study, Arch Intern Med, vol.160, issue.5, pp.661-667, 2000.

L. Zheng, W. Yan, Y. Kong, P. Liang, and Y. Mu, An epidemiological study of risk factors of thyroid nodule and goiter in Chinese women, Int J Clin Exp Med, vol.8, issue.7, pp.11379-87, 2015.

P. De-sousa, M. Vaisman, J. Carneiro, L. Guimarães, H. Freitas et al., Prevalence of goiter and thyroid nodular disease in patients with class III obesity, Arq Bras Endocrinol Metabol, vol.57, issue.2, pp.120-125, 2013.

M. C. Vantyghem, F. Faivre-defrance, S. Marcelli-tourvieille, C. Fermon, A. Evrard et al., Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism, Clin Endocrinol, vol.67, issue.2, pp.247-256, 2007.

A. Johansson, T. Olsson, K. Cederquist, H. Forsberg, J. J. Holst et al., Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy, Eur J Endocrinol, vol.146, issue.3, pp.397-405, 2002.

M. Vujnic, S. Peric, S. Popovic, N. Raseta, V. Ralic et al., Metabolic syndrome in patients with myotonic dystrophy type 1, Muscle Nerve, vol.52, issue.2, pp.273-280, 2015.

C. Terracciano, E. Rastelli, M. Morello, M. Celi, E. Bucci et al., Vitamin D deficiency in myotonic dystrophy type 1, J Neurol, vol.260, issue.9, pp.2330-2334, 2013.

M. B. Zimmermann and K. Boelaert, Iodine deficiency and thyroid disorders, Lancet Diabetes Endocrinol, vol.3, issue.4, pp.286-95, 2015.

J. Ma, D. Wu, C. Li, C. Fan, N. Chao et al., Lower serum 25-Hydroxyvitamin D level is associated with 3 types of autoimmune thyroid diseases, Medicine (Baltimore), vol.94, issue.39, p.1639, 2015.

S. Meng, S. He, W. Jiang, X. L. Li, D. Xu et al., Genetic susceptibility to autoimmune thyroid diseases in a Chinese Han population: role of vitamin D receptor gene polymorphisms, Ann Endocrinol (Paris), vol.76, issue.6, pp.684-693, 2015.

S. Christakos, P. Dhawan, A. Verstuyf, L. Verlinden, and G. Carmeliet, Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects, Physiol Rev, vol.96, issue.1, pp.365-408, 2016.

A. Mousa, N. Naderpoor, M. De-courten, R. Scragg, and B. De-courten, 25-hydroxyvitamin D is associated with adiposity and cardiometabolic risk factors in a predominantly vitamin D-deficient and overweight/obese but otherwise healthy cohort, J Steroid Biochem Mol Biol, vol.173, pp.258-64, 2017.

C. Daumerie, N. Lannoy, J. P. Squifflet, G. Verellen, and C. Verellen-dumoulin, High CTG repeat number in nodular thyroid tissue from a myotonic dystrophy patient, J Med Genet, vol.31, issue.11, pp.891-893, 1994.